Related Experiment Videos
[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]
Nihon Sanka Fujinka Gakkai Zasshi
|September 1, 1985
Summary
Tissue polypeptide antigen (TPA) monitoring in gynecologic cancers shows elevated levels correlate with advanced disease stages. While not tumor-specific, serial TPA measurements aid in tracking treatment effectiveness and patient prognosis.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Context:
- Gynecologic cancers represent a significant health concern globally.
- Accurate tumor markers are crucial for early detection and monitoring of gynecologic malignancies.
- Tissue polypeptide antigen (TPA) is a biomarker investigated for its potential role in gynecologic oncology.
Purpose:
- To evaluate the diagnostic and prognostic value of serum Tissue polypeptide antigen (TPA) in patients with gynecologic tumors.
- To assess the correlation between TPA levels and the stage of gynecologic malignancies.
- To determine the utility of serial TPA measurements in monitoring treatment response and clinical course.
Summary:
- Serum TPA levels were measured in 413 patients with various gynecologic tumors using radioimmunoassay.
- Elevated TPA levels were observed to increase with advancing disease stages in cervical, endometrial, and ovarian cancers.
- While TPA lacks tumor specificity, showing elevated levels in benign conditions, serial measurements correlated with treatment efficacy and clinical outcomes.
Impact:
- TPA's lack of tumor specificity limits its standalone diagnostic utility in gynecologic malignancies.
- Serial TPA measurements can serve as a valuable tool for monitoring treatment response and patient follow-up in gynecologic oncology.
- Further research may explore TPA in combination with other markers for improved diagnostic accuracy.